发明名称 SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors
摘要 Particular aspects provide for use of the -herpesvirus Cytomegalovirus (CMV: e.g., RhCMV and HCMV) as a uniquely evolved "vector" for safely initiating and indefinitely maintaining high level cellular and humoral immune responses (against, e.g., HIV, SIV, TB, etc.). Particular aspects provide a method for treatment or prevention of, e.g., HIV, SIV or TB, comprising infection of a subject in need thereof with at least one recombinant CMV-based vector (e.g., HCMV or RhCMV) comprising an expressible HIV/SIV/TB antigen or a variant or fusion protein thereof. In particular embodiments of the method, infection is of an immunocompetent, HCMV or RhCMV seropositive subject. Additional aspects provide for RhCMV- and HCMV-based vaccine vectors, and versions thereof with suicide or safety means. Further aspects provide pharmaceutical compositions comprising the inventive CMV-based vaccine vectors.
申请公布号 AU2005285513(B2) 申请公布日期 2011.02.24
申请号 AU20050285513 申请日期 2005.05.25
申请人 OREGON HEALTH AND SCIENCE UNIVERSITY 发明人 MICHAEL JARVIS;JAY A. NELSON;LOUIS J. PICKER
分类号 C12N15/63 主分类号 C12N15/63
代理机构 代理人
主权项
地址